alemtuzumab + filgrastim + sirolimus

This is a combination regimen consisting of three agents: - **Alemtuzumab** is a humanized monoclonal antibody targeting CD52, expressed on the surface of mature lymphocytes. It induces profound lymphocyte depletion via antibody-dependent cellular cytolysis and complement-mediated lysis, leading to immunosuppression. Alemtuzumab is primarily used in B-cell chronic lymphocytic leukemia and relapsing multiple sclerosis, but also as part of conditioning or induction regimens in transplantation[5][2]. - **Filgrastim** is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursors, thereby increasing neutrophil counts. It is commonly used to reduce the risk of infection due to neutropenia from chemotherapy or immunosuppressive therapy[1]. - **Sirolimus** (also known as rapamycin) is an mTOR inhibitor with potent immunosuppressive properties. It inhibits T-cell activation and proliferation by blocking IL-2 signal transduction pathways. Sirolimus is widely used for prevention of organ transplant rejection and as part of graft-versus-host disease (GVHD) prophylaxis regimens[6][2]. The combination may be considered in experimental or off-label settings such as hematopoietic stem cell transplantation or solid organ transplantation for its synergistic effects on immune modulation—alemtuzumab for profound lymphodepletion, filgrastim for hematopoietic support during periods of cytopenia induced by alemtuzumab, and sirolimus for ongoing maintenance immunosuppression[1][2][9]. This regimen carries significant risks including severe leukopenia/myelosuppression, increased infection risk (notably CMV reactivation), delayed engraftment/recovery, and other toxicities.